Biologics CDMO Market Trends 2025-2034: Growth, Strategic Insights, and Opportunities Ahead
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What Major Innovations Are Driving the Accelerated Growth of the Biologics CDMO Market?
The increase in need for cell and gene therapy is projected to accelerate the expansion of the biologic CDMO market in the future. Both cell and gene therapy are novel medical strategies that employ living cells or genetic matter to tackle the root causes of diseases on a cellular or genetic scale, offering potential remedies for illnesses that are tough to treat or untreatable using conventional pharmaceuticals. The desire for cell and gene treatment is on the rise due to its potential to contribute ground-breaking cures for diseases by confronting underlying cellular or genetic factors. Biologic CDMOs play a crucial role in handling living cells, viral vectors, and genetic matter efficiently and safely, thereby enabling smooth production of cell and gene treatments while aiding biopharmaceutical companies in meeting regulatory compliance and overcoming technical hurdles, hence aiding in the transition from research to clinical application. For example, in January 2023, the The American Society of Gene & Cell Therapy (ASGCT), a predominant US-based professional association, reported that the gene, cell and RNA therapy pipeline experienced 7% growth in 2022, totalling 3,726 therapies under development. Among these, gene therapies account for 55%, non-genetically modified cell therapies contribute 22%, and RNA therapies make up 23%. Consequently, the increasing demand for cell and gene therapy is fueling the expansion of the biologic CDMO market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp
#What is the Projected CAGR for the Biologics CDMO Market Size from 2025 to 2034?
The size of the biologics cdmo market has seen impressive growth recently. It is projected to increase from $21.3 billion in 2024 to $24.37 billion in 2025, with a compound annual growth rate (CAGR) of 14.4%. The notable growth during the historic period is due to factors such as increased development of biologics, cost-effectiveness and adaptability, emphasis on key competencies, regulatory adherence and quality assurance, and the expansion of pharmaceutical supply chains globally.
Anticipations for the biologics cdmo market size showcase a swift expansion in the forthcoming years, escalating to $42.33 billion by 2029 with a CAGR of 14.8%. This prosperous surge over the projection era can be ascribed to the escalating demand for biologic therapies, the emergence of biosimilars and biobetters, injections into biomanufacturing infrastructure, the shift to the outsourcing of intricate processes, concentration on improving supply chain resilience and risk management, assimilation of regulatory guidelines, and fast-tracked approvals. The upcoming trends within this projection period are the expansion of capabilities to provide comprehensive solutions, acceptance of single-use technologies, incorporation of continuous manufacturing processes and the arrival of specialized CDMOs.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14056
What Are the Most Significant Market Trends Transforming theBiologics CDMO Market?
Major companies operating in the biologics CDMO market are developing technologically advanced solutions, such as new cell lines, to enhance biopharmaceutical development and manufacturing efficiency and capabilities. The technology produces therapeutic antibodies with enhanced potency, addressing immunotherapy research and development challenges. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturing company that specializes in the pharmaceutical and biotechnology sectors, launched GS Effex cell lines, designed to produce antibodies that are 100% free of fucose, a sugar molecule and demonstrate increased potency without compromising on other performance attributes. It helps overcome immunotherapy research and development challenges related to the need for antibody therapeutics to increase potency. It is a stable, scalable, and productive cell line that provides a solution for therapeutic development from discovery-stage research through commercial manufacturing.
What Are the Top Market Players Propelling the Growth of theBiologics CDMO Industry?
Major companies operating in the biologics CDMO market are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report
Which Primary Segments of the Biologics CDMO Market Are Driving Growth and Industry Transformations?
The biologics cdmo market covered in this report is segmented –
1) By Cell Type: Mammalian, Non-Mammalian
2) By Product Type: Biologics, Biosimilars
Subsegments:
1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells
2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=14056&type=smp
Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Biologics CDMO Market?# Market?
North America was the largest region in the biologics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Reports Similar to the Global Biologics CDMO Market 2025, By The Business Research Company:
Privileged Access Management Solutions Global Market Report 2024
Multi-Access Edge Computing Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/multi-access-edge-computing-global-market-report
Physical Identity And Access Management Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
